IL138424A - Covalently reactive antigen analogs and pharmaceutical compositions containing the same - Google Patents

Covalently reactive antigen analogs and pharmaceutical compositions containing the same

Info

Publication number
IL138424A
IL138424A IL13842499A IL13842499A IL138424A IL 138424 A IL138424 A IL 138424A IL 13842499 A IL13842499 A IL 13842499A IL 13842499 A IL13842499 A IL 13842499A IL 138424 A IL138424 A IL 138424A
Authority
IL
Israel
Prior art keywords
antigen analogs
same
pharmaceutical compositions
reactive antigen
compositions containing
Prior art date
Application number
IL13842499A
Other languages
English (en)
Other versions
IL138424A0 (en
Original Assignee
Univ Nebraska
Larry J Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska, Larry J Smith filed Critical Univ Nebraska
Publication of IL138424A0 publication Critical patent/IL138424A0/xx
Publication of IL138424A publication Critical patent/IL138424A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
IL13842499A 1998-03-23 1999-03-23 Covalently reactive antigen analogs and pharmaceutical compositions containing the same IL138424A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/046,373 US6235714B1 (en) 1998-03-23 1998-03-23 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
PCT/US1999/006325 WO1999048925A1 (en) 1998-03-23 1999-03-23 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses

Publications (2)

Publication Number Publication Date
IL138424A0 IL138424A0 (en) 2001-10-31
IL138424A true IL138424A (en) 2005-08-31

Family

ID=21943098

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13842499A IL138424A (en) 1998-03-23 1999-03-23 Covalently reactive antigen analogs and pharmaceutical compositions containing the same

Country Status (16)

Country Link
US (3) US6235714B1 (de)
EP (1) EP1064308B1 (de)
JP (2) JP2002507627A (de)
KR (1) KR100748920B1 (de)
CN (1) CN100358920C (de)
AT (1) ATE404587T1 (de)
AU (1) AU760648B2 (de)
BR (1) BR9909011A (de)
CA (1) CA2324340A1 (de)
DE (1) DE69939312D1 (de)
ES (1) ES2313780T3 (de)
IL (1) IL138424A (de)
PL (1) PL343245A1 (de)
RU (1) RU2226401C2 (de)
TR (1) TR200002731T2 (de)
WO (1) WO1999048925A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855804B2 (en) 1998-03-23 2005-02-15 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
US20050043262A1 (en) * 2000-03-29 2005-02-24 Weiss Robert H. Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor
CA2442693A1 (en) * 2001-03-31 2002-10-10 Board Of Regents, The University Of Texas System Covalently reactive transition state analogs and methods of use thereof
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
FR2825154B1 (fr) * 2001-05-22 2004-01-30 Univ Compiegne Tech Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique
AU2002336650B2 (en) 2001-10-25 2008-06-05 Emory University Catheter for modified perfusion
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
JP5253325B2 (ja) * 2002-09-04 2013-07-31 中外製薬株式会社 ＭＲＬ／ｌｐｒマウスを用いた抗体の作製
JP2006501856A (ja) * 2002-10-09 2006-01-19 インテグリジェン， インコーポレイテッド 組換え触媒ポリペプチドおよびその使用
EP1615946B1 (de) * 2003-03-26 2020-05-06 Sudhir Paul Proteolytische und kovalente antikörper
US9006388B2 (en) * 2003-03-26 2015-04-14 Sudhir Paul Covalent attachment of ligands to nucleophilic proteins guided by non-covalent
EP1613643A4 (de) * 2003-03-27 2009-10-28 Sudhir Paul Lupus-antikörper zur passiven immuntherapie von hiv/aids
US20050084488A1 (en) * 2003-04-10 2005-04-21 Mulkerrin Michael G. Asparagine deaminase catalytic antibodies
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
WO2005037228A2 (en) * 2003-10-17 2005-04-28 Integrigen, Inc. Halogen phosphonate monoesters
WO2005099772A2 (en) * 2004-04-13 2005-10-27 Boston Biomedical Research Institute Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death
KR101400505B1 (ko) 2004-08-20 2014-05-28 버크 인스티튜트 포 에이지 리서치 Ｐ５３ 기능을 대체하거나 작동시키는 소형 분자
JP2008525468A (ja) * 2004-12-22 2008-07-17 エモリー・ユニバーシティ ポストコンディショニング臓器保護作用を増強する治療補助薬
EP1989326A4 (de) 2006-01-17 2009-09-30 Health Research Inc Heteroduplex-verfolgungstest
US20090117115A1 (en) * 2006-11-09 2009-05-07 Sudhir Paul Binary epitope antibodies and B cell superantigen immune stimulants
EP2452947A1 (de) * 2010-11-16 2012-05-16 Münch, Jan Eine Viralinfektion steigerndes Peptid
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
ES2687974T3 (es) 2012-03-14 2018-10-30 Regeneron Pharmaceuticals, Inc. Moléculas multiespecíficas de unión a antígeno y uso de las mismas
MY197218A (en) 2015-07-06 2023-06-02 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (de) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Verfahren zur herstellung multispezifischer antigenbindender moleküle
US20200101076A1 (en) * 2018-09-28 2020-04-02 Harrow Ip, Llc Pharmaceutical compositions for prevention or treatment of cytokine release syndrome
CN112245563A (zh) * 2020-09-29 2021-01-22 古鲟（大连）生物科技发展有限公司 可降尿酸的鲟鱼肽复合粉

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
US5658753A (en) * 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
JPH05503284A (ja) * 1989-06-08 1993-06-03 イゲン，インコーポレイテッド 準安定結合の修飾速度を上昇する方法
US5948658A (en) * 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody

Also Published As

Publication number Publication date
EP1064308A1 (de) 2001-01-03
KR100748920B1 (ko) 2007-08-14
BR9909011A (pt) 2000-11-28
PL343245A1 (en) 2001-07-30
CA2324340A1 (en) 1999-09-30
EP1064308A4 (de) 2004-08-11
CN100358920C (zh) 2008-01-02
CN1301271A (zh) 2001-06-27
WO1999048925A1 (en) 1999-09-30
US20020013274A1 (en) 2002-01-31
TR200002731T2 (tr) 2001-04-20
ATE404587T1 (de) 2008-08-15
US6855528B2 (en) 2005-02-15
ES2313780T3 (es) 2009-03-01
US20050214295A1 (en) 2005-09-29
IL138424A0 (en) 2001-10-31
AU760648B2 (en) 2003-05-22
AU3111399A (en) 1999-10-18
EP1064308B1 (de) 2008-08-13
JP2002507627A (ja) 2002-03-12
DE69939312D1 (de) 2008-09-25
RU2226401C2 (ru) 2004-04-10
JP2010031016A (ja) 2010-02-12
KR20010042123A (ko) 2001-05-25
US6235714B1 (en) 2001-05-22

Similar Documents

Publication Publication Date Title
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
MX9707021A (es) Receptor de il-7.
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
PT1157042E (pt) Produção de anticorpos tetravalentes
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
AP9801392A0 (en) Concentrated antibody preparation.
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
HUP0103758A2 (hu) Neurotróf faktorok
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
ATE325803T1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
FR2717081B1 (fr) Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
EP0955366A4 (de) Antigenes protein aus malassezia
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
PT1196188E (pt) Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
IL89857A0 (en) Human monoclonal antibodies specifically recognizing rabies virus hybridoma,cells producing them,pharmaceutical compositions containing them and their production
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
FR2608926B1 (fr) Antigene de babesia divergens, procede pour le produire et vaccin le contenant

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees